Cargando…

Hepatitis C Virus Treatment Revolution: Eastern European Story

Hepatitis C can be cured and even eradicated by new “revolutionary” treatments. However, at present exorbitant prices, Eastern European countries cannot afford the new treatments, while in western rich and developed countries (e.g. Germany and France) they are already available. Concerted efforts of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stanciu, Carol, Trifan, Anca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2015
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539731/ https://www.ncbi.nlm.nih.gov/pubmed/26300932 http://dx.doi.org/10.5812/hepatmon.28969v2

Ejemplares similares

Lactoferrin Inhibits Hepatitis C Virus Viremia in Patients with Chronic Hepatitis C: A Pilot Study
por: Tanaka, Katsuaki, et al.
Publicado: (1999)

Transition of Antibody to Hepatitis C Virus from Chronic Hepatitis to Hepatocellular Carcinoma
por: Kiyosawa, Kendo, et al.
Publicado: (1990)

Frequent Detection of Hepatitis C Virus US Strain in Japanese Hemophiliacs
por: Hijikata, Makoto, et al.
Publicado: (1990)

Detection of West Nile virus lineage 2 in North‐Eastern Spain (Catalonia)
por: Busquets, Núria, et al.
Publicado: (2018)

Increased Prevalence of HTLV‐I Infection in Patients with Hepatocellular Carcinoma Associated with Hepatitis C Virus
por: Okayama, Akihiko, et al.
Publicado: (1995)

Detection of Hepatitis C Virus RNA in Sera and Liver Tissues of Non‐A, Non‐B Hepatitis Patients Using the Polymerase Chain Reaction
por: Ohkoshi, Showgo, et al.
Publicado: (1990)

Massive Sero–epidemiological Survey of Hepatitis C Virus: Clustering of Carriers on the Southwest Coast of Tsushima, Japan
por: Ito, Shin‐Ichiro, et al.
Publicado: (1991)

The story of fake impact factor companies and how we detected them
por: Jalalian, Mehrdad
Publicado: (2015)

Headache associated with moyamoya disease: a case story and literature review
por: Zach, Victor, et al.
Publicado: (2009)

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study
por: Nelson, David R, et al.
Publicado: (2015)

A Structural Protein Encoded by the 5′ Region of the Hepatitis C Virus Genome Efficiently Detects Viral Infection
por: Kato, Nobuyuki, et al.
Publicado: (1990)

Detection of novel tick-borne pathogen, Alongshan virus, in Ixodes ricinus ticks, south-eastern Finland, 2019
por: Kuivanen, Suvi, et al.
Publicado: (2019)

Detection of Hepatitis C Virus Infection by Enzyme‐linked Immunosorbent Assay System Using Core Protein Expressed in Escherichia coli
por: Muraiso, Kanae, et al.
Publicado: (1991)

Autophagy protein ATG5 interacts transiently with the hepatitis C virus RNA polymerase (NS5B) early during infection
por: Guévin, Carl, et al.
Publicado: (2010)

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)
por: Leroy, Vincent, et al.
Publicado: (2016)

Virological surveillance of influenza viruses in the WHO European Region in 2019/20 – impact of the COVID-19 pandemic
por: Melidou, Angeliki, et al.
Publicado: (2020)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Impact of the COVID-19 pandemic on testing services for HIV, viral hepatitis and sexually transmitted infections in the WHO European Region, March to August 2020
por: Simões, Daniel, et al.
Publicado: (2020)

Murine hepatitis virus nsp4 N258T mutants are not temperature-sensitive
por: Beachboard, Dia C., et al.
Publicado: (2013)

X Protein of Hepatitis B Virus Resembles a Serine Protease Inhibitor
por: Takada, Shinako, et al.
Publicado: (1990)

Reduction in undiagnosed HIV infection in the European Union/European Economic Area, 2012 to 2016
por: van Sighem, Ard, et al.
Publicado: (2017)

Influenza returns with a season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region, 2021/22
por: Melidou, Angeliki, et al.
Publicado: (2022)

Will we reach the Sustainable Development Goals target for tuberculosis in the European Union/European Economic Area by 2030?
por: Merk, Hanna, et al.
Publicado: (2019)

Monitoring the progress achieved towards ending tuberculosis in the European Union/European Economic Area, 2018 to 2021
por: Cristea, Veronica, et al.
Publicado: (2023)

Demethylation by 5‐Azacytidine Results in the Expression of Hepatitis B Virus Surface Antigen in Transgenic Mice
por: Araki, Kimi, et al.
Publicado: (1989)

Estimating HIV incidence and number of undiagnosed individuals living with HIV in the European Union/European Economic Area, 2015
por: Pharris, Anastasia, et al.
Publicado: (2016)

Health crisis in Venezuela: Status of communicable diseases and implications for the European Union and European Economic Area, May 2019
por: Espinosa, Laura, et al.
Publicado: (2019)

Potential scenarios for the progression of a COVID-19 epidemic in the European Union and the European Economic Area, March 2020
por: Johnson, Helen C, et al.
Publicado: (2020)

Need for additional capacity and improved capability for molecular detection of yellow fever virus in European Expert Laboratories: External Quality Assessment, March 2018
por: Domingo, Cristina, et al.
Publicado: (2018)

Ongoing outbreaks of hepatitis A among men who have sex with men (MSM), Berlin, November 2016 to January 2017 – linked to other German cities and European countries
por: Werber, Dirk, et al.
Publicado: (2017)

Shortened Telomere Length in Hepatocellular Carcinomas and Corresponding Background Liver Tissues of Patients Infected with Hepatitis Virus
por: Ohashi, Kazuo, et al.
Publicado: (1996)

Hepatitis delta virus-like circular RNAs from diverse metazoans encode conserved hammerhead ribozymes
por: de la Peña, Marcos, et al.
Publicado: (2021)

Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017
por: Kohlenberg, Anke, et al.
Publicado: (2018)

Candida auris: epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area*, January 2018 to May 2019
por: Plachouras, Diamantis, et al.
Publicado: (2020)

Severe acute hepatitis and acute liver failure of unknown origin in children: a questionnaire-based study within 34 paediatric liver centres in 22 European countries and Israel, April 2022
por: de Kleine, Ruben H, et al.
Publicado: (2022)

Rapid cross-border emergence of NDM-5-producing Escherichia coli in the European Union/European Economic Area, 2012 to June 2022
por: Linkevicius, Marius, et al.
Publicado: (2023)

From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and “augmented” medicine: some considerations on Salvatore Iaconesi’s clinical story
por: Bragazzi, Nicola Luigi
Publicado: (2013)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015)

Decreasing and stabilising trends of antimicrobial consumption and resistance in Escherichia coli and Klebsiella pneumoniae in segmented regression analysis, European Union/European Economic Area, 2001 to 2018
por: Peñalva, Germán, et al.
Publicado: (2019)

Rapidly increasing cumulative incidence of coronavirus disease (COVID-19) in the European Union/European Economic Area and the United Kingdom, 1 January to 15 March 2020
por: Kinross, Pete, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_klqmdn7615mhkp4i36hoisc15k